Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antiwei Granules for Common Cold (Wind-cold Syndrome)
NCT06697886Phase 3Recruiting
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd.
- Start
- Nov 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Antiwei Granules in common cold (2 arms), sponsored by Tasly Pharmaceutical Group Co., Ltd. Primary endpoint: Cure rate after 3 days of treatment. Started Nov 2023; status: recruiting.
02
Drugs
Antiwei Granules
03
Conditions
common cold
Beyond the preview
Go deeper on NCT06697886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06697886.